| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TUBE.2007.05.012 |
| P698 | PubMed publication ID | 17950035 |
| P50 | author | Chang-Seok Ki | Q38641833 |
| Won-Jung Koh | Q60960471 | ||
| P2093 | author name string | Jong-Won Kim | |
| Soo-Youn Lee | |||
| Hyun-Jung Cho | |||
| Myung-Hyun Nam | |||
| Yon-Ju Ryu | |||
| P2860 | cites work | Criteria of drug-induced liver disorders. Report of an international consensus meeting | Q34271897 |
| CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis | Q34568319 | ||
| Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study | Q36512029 | ||
| Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis | Q40477722 | ||
| Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients | Q40518383 | ||
| Risk Factors for Isoniazid (INH)-Induced Liver Dysfunction | Q42269734 | ||
| Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans | Q42288254 | ||
| Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype | Q42538095 | ||
| Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis | Q43933944 | ||
| Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis | Q44385947 | ||
| CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence | Q44460551 | ||
| The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients | Q46719027 | ||
| DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity | Q46772060 | ||
| A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. | Q50966347 | ||
| Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection | Q58236138 | ||
| Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites | Q66956036 | ||
| Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide | Q69651788 | ||
| Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype | Q70030199 | ||
| Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma | Q71737236 | ||
| Drug-induced hepatotoxicity | Q71758942 | ||
| Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene | Q73004017 | ||
| In vivo modulation of CYP enzymes by quinidine and rifampin | Q73148564 | ||
| Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis | Q73712041 | ||
| A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake | Q77410008 | ||
| P433 | issue | 6 | |
| P921 | main subject | tuberculosis | Q12204 |
| patient | Q181600 | ||
| hepatotoxicity | Q1349821 | ||
| P304 | page(s) | 551-556 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Tuberculosis | Q15757844 |
| P1476 | title | Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis | |
| P478 | volume | 87 |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q37613934 | A guide to the management of tuberculosis in patients with chronic liver disease |
| Q35774965 | Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes |
| Q35096954 | Antituberculosis drug-induced hepatotoxicity in children |
| Q42696912 | Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. |
| Q45344839 | Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India |
| Q54217783 | Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. |
| Q93064850 | Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population |
| Q92376682 | Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis |
| Q46637665 | Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil |
| Q59336366 | CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis |
| Q43754598 | CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study |
| Q42335970 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines |
| Q28486869 | Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort |
| Q37440644 | Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutations |
| Q39037269 | Drug metabolism and liver disease: a drug-gene-environment interaction |
| Q37736444 | Drug-induced liver injury: past, present and future. |
| Q38084215 | Drug-induced liver injury: the role of drug metabolism and transport |
| Q36247566 | Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication |
| Q64949354 | Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. |
| Q51316163 | Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil. |
| Q45565570 | GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs |
| Q43207061 | GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans |
| Q37931275 | Genetic association studies in drug-induced liver injury |
| Q43611407 | Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients |
| Q42916623 | Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients |
| Q43248041 | Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis |
| Q43145481 | Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity |
| Q43275327 | Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population |
| Q47184878 | Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives |
| Q39158128 | Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation |
| Q92170011 | Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients |
| Q33901424 | Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol) |
| Q91588243 | Isoniazid acetylation phenotypes in the Sudanese population; findings and implications |
| Q28076859 | Isoniazid metabolism and hepatotoxicity |
| Q43885443 | Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population |
| Q57302643 | N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group |
| Q45766101 | N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians |
| Q83687295 | N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine |
| Q54314510 | NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. |
| Q35934555 | NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis |
| Q38865905 | Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. |
| Q42090708 | PharmGKB summary: isoniazid pathway, pharmacokinetics. |
| Q27011622 | PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 |
| Q28484468 | Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis |
| Q57302676 | Pharmacogenetics of Adverse Drug Reactions |
| Q27015820 | Pharmacogenomics of adverse drug reactions |
| Q37096055 | Pharmacogenomics of anti-TB drugs-related hepatotoxicity |
| Q34977413 | Pharmacogenomics of antimicrobial agents |
| Q91927814 | Pharmacokinetics of isoniazid: The good, the bad, and the alternatives |
| Q26863380 | Risk factors associated with adverse reactions to antituberculosis drugs |
| Q53765768 | Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. |
| Q37732312 | Role of CYP3A in isoniazid metabolism in vivo |
| Q36441540 | Role of pharmacogenomics in the treatment of tuberculosis: a review |
| Q42284821 | Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. |
| Q43474583 | Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis |
| Q51569750 | Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. |
| Q64969857 | The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. |
| Q38977166 | The challenges of pharmacokinetic variability of first-line anti-TB drugs |
| Q37835918 | The impact of CYP2E1 genetic variability on risk assessment of VOC mixtures |
| Q28539060 | The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1 |
| Q38213320 | Therapeutic drug monitoring in the treatment of tuberculosis: an update |
| Q38381479 | Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies |
| Q35120591 | Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients |
| Q64079129 | variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis |
Search more.